Aterovax develops innovative solutions to predict , diagnose, prevent and treat cardiovascular disease through its unique understanding of atherosclerosis.

Our first product, ATEROVAX sPLA2 Activity Test, is now available for research use only. The test detects the activity of the enzyme sPLA2, which has been validated as a potent biomarker of the vulnerable or destabilised atherosclerotic plaque.